Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy ; volume:199 ; number:2 ; day:22 ; month:3 ; year:2023 ; pages:231-241 ; date:6.2023
Breast cancer research and treatment ; 199, Heft 2 (22.3.2023), 231-241, 6.2023
- Urheber
-
Iwata, Hiroji
Yamamoto, Yutaka
Sakai, Takehiko
Hasegawa, Yoshie
Nakamura, Rikiya
Akabane, Hiromitsu
Ohtani, Shoichiro
Kashiwaba, Masahiro
Taira, Naruto
Toyama, Tatsuya
Fujisawa, Tomomi
Masuda, Norikazu
Shibahara, Yukiko
Sasano, Hironobu
Yamaguchi, Takuhiro
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10549-023-06874-7
- URN
-
urn:nbn:de:101:1-2023090713272943689240
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:55 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Iwata, Hiroji
- Yamamoto, Yutaka
- Sakai, Takehiko
- Hasegawa, Yoshie
- Nakamura, Rikiya
- Akabane, Hiromitsu
- Ohtani, Shoichiro
- Kashiwaba, Masahiro
- Taira, Naruto
- Toyama, Tatsuya
- Fujisawa, Tomomi
- Masuda, Norikazu
- Shibahara, Yukiko
- Sasano, Hironobu
- Yamaguchi, Takuhiro
- SpringerLink (Online service)
Ähnliche Objekte (12)
SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer
Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer
Factors influencing the initiation of adjuvant endocrine therapy in patients with estrogen receptor-positive ductal carcinoma in situ: a single institution experience
microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer
Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer
Endocrine disrupting chemicals : interaction with estrogen receptors an in vitro assessment of endocrine activity potential
Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer
Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen
Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer
Efficacy of adjuvant chemotherapy stratified by age and the 21-gene recurrence score in estrogen receptor-positive breast cancer
Endosomal recycling inhibitors downregulate estrogen receptor-alpha and synergise with endocrine therapies
SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer
Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer
Factors influencing the initiation of adjuvant endocrine therapy in patients with estrogen receptor-positive ductal carcinoma in situ: a single institution experience
microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer
Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer
Endocrine disrupting chemicals : interaction with estrogen receptors an in vitro assessment of endocrine activity potential
Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer
Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen
Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer
Efficacy of adjuvant chemotherapy stratified by age and the 21-gene recurrence score in estrogen receptor-positive breast cancer
Endosomal recycling inhibitors downregulate estrogen receptor-alpha and synergise with endocrine therapies
SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer
Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer
Factors influencing the initiation of adjuvant endocrine therapy in patients with estrogen receptor-positive ductal carcinoma in situ: a single institution experience
microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer
Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer
Endocrine disrupting chemicals : interaction with estrogen receptors an in vitro assessment of endocrine activity potential
Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer
Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen
Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer
Efficacy of adjuvant chemotherapy stratified by age and the 21-gene recurrence score in estrogen receptor-positive breast cancer